How would you manage adjuvant endocrine therapy for a postmenopausal patient with early stage HR+ breast CA who develops an ischemic CVA on an AI?

Topics: Breast Cancer • Medical Oncology • HR+ • Neurology

Presuming that work-up for cardioembolic sources is negative, how would you proceed?

Answer from: Medical Oncologist at Academic Institution

This is a vexing problem that I myself have had to deal with. My patient developed a TIA on aromatase inhibitor (AI). Work up was negative for predisposing risk factors. The choice was easy in this case. This woman was told by her family friend, who was a doctor, that AIs cause stroke and she refuse...

Comments

Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
Thanks for this information. These references comp...

Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
I would recommend low-dose tamoxifen 5 mg/day for ...

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
Thanks for your thoughtful and detailed replies. M...

Medical Oncologist at Icahn School of Medicine at Mount Sinai
Tamoxifen vs placebo the ischemic stroke risk is s...

Related Questions